Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Tango Therapeutics (TNGX) Income from Continuing Operations (2020 - 2025)

Tango Therapeutics has reported Income from Continuing Operations over the past 6 years, most recently at 38749000.0 for Q4 2025.

  • Quarterly results put Income from Continuing Operations at 38749000.0 for Q4 2025, down 2.86% from a year ago — trailing twelve months through Dec 2025 was 101594000.0 (up 22.03% YoY), and the annual figure for FY2025 was 101594000.0, up 22.03%.
  • Income from Continuing Operations for Q4 2025 was 38749000.0 at Tango Therapeutics, down from 15884000.0 in the prior quarter.
  • Over the last five years, Income from Continuing Operations for TNGX hit a ceiling of 15884000.0 in Q3 2025 and a floor of 39876000.0 in Q1 2025.
  • Median Income from Continuing Operations over the past 5 years was 26779500.0 (2023), compared with a mean of 25004100.0.
  • Biggest five-year swings in Income from Continuing Operations: tumbled 951806.78% in 2021 and later surged 154.46% in 2025.
  • Tango Therapeutics' Income from Continuing Operations stood at 22054000.0 in 2021, then tumbled by 31.77% to 29060000.0 in 2022, then fell by 5.82% to 30750000.0 in 2023, then fell by 22.5% to 37670000.0 in 2024, then decreased by 2.86% to 38749000.0 in 2025.
  • The last three reported values for Income from Continuing Operations were 38749000.0 (Q4 2025), 15884000.0 (Q3 2025), and 38853000.0 (Q2 2025) per Business Quant data.